SCHEMBL16446508

SCHEMBL16446508

CCOC(=O)Cc1ccc(-n2ccc3c(C)nc(-c4ccc(OC)c(Cl)c4)nc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PDE4B Q07343 6/20 0.60
▸ TUBB4A P04350 1/20 0.38
▸ TUBB P07437 1/20 0.38
▸ TUBA3C P0DPH7 1/20 0.38
▸ TUBA1B P68363 1/20 0.38
▸ TUBA4A P68366 1/20 0.38
▸ TUBB4B P68371 1/20 0.38
▸ TUBB3 Q13509 1/20 0.38
▸ TUBB2A Q13885 1/20 0.38
▸ TUBB8 Q3ZCM7 1/20 0.38
▸ TUBA3E Q6PEY2 1/20 0.38
▸ TUBA1A Q71U36 1/20 0.38
▸ TUBA1C Q9BQE3 1/20 0.38
▸ TUBB6 Q9BUF5 1/20 0.38
▸ TUBB2B Q9BVA1 1/20 0.38
▸ TUBB1 Q9H4B7 1/20 0.38
▸ PDE4D Q08499 2/20 0.38
▸ GRIN2B Q13224 1/20 0.37
▸ PDE5A O76074 1/20 0.36
▸ PTGS2 P35354 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16446217 0.90 PDE4B (0.65) PDE4BPDE4DPTGS2PIP4K2APTGS1
SCHEMBL16446938 0.84 PDE4B (0.82) PDE4BPDE5APTGS2PIP4K2APTGS1
SCHEMBL16445876 0.83 PDE4B (0.68) PDE4BPDE4DPTGS2PIP4K2APTGS1
SCHEMBL16446605 0.79 PDE4B (0.51) PDE4BPDE4DPTGS2KDM4EMAPT
SCHEMBL16446337 0.75 PDE4B (1.00) PDE4BPDE5APTGS2PIP4K2A
SCHEMBL16446612 0.74 PDE4B (0.84) PDE4BPDE4DPTGS2PIP4K2APTGS1
SCHEMBL16446387 0.73 PDE4B (0.61) PDE4BPDE4DPTGS2KDM4EMAPT
SCHEMBL16447006 0.73 PDE4B (0.64) PDE4BPDE5APTGS2PTGS1HTT
SCHEMBL16447005 0.73 PDE4B (0.64) PDE4BPDE5APTGS2PTGS1HTT
SCHEMBL16446770 0.72 PDE4B (0.59) PDE4BPDE4DPTGS2PTGS1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3030565-B1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS GRUENENTHAL GMBH (DE) 2017-07-19 — — EP disclosed
US-9688683-B2 Substituted condensed pyrimidine compounds Grünenthal GmbH (DE) 2017-06-27 — — US disclosed
EP-3030565-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-15 — — EP disclosed
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2016-06-02 — — US disclosed
WO-2015018534-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS Grünenthal GmbH (DE) 2015-02-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160152624-A1 NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS PDE4A, PDE4B, TYMP PDE4B 2/4885TUBB4A 233/4885TUBB 711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback